Krishna Institute of Medical Sciences Limited (NSE:KIMS)
721.65
+3.65 (0.51%)
Oct 28, 2025, 3:30 PM IST
NSE:KIMS Revenue
Krishna Institute of Medical Sciences had revenue of 8.72B INR in the quarter ending June 30, 2025, with 26.61% growth. This brings the company's revenue in the last twelve months to 32.18B, up 24.71% year-over-year. In the fiscal year ending March 31, 2025, Krishna Institute of Medical Sciences had annual revenue of 30.35B with 21.49% growth.
Revenue (ttm)
32.18B
Revenue Growth
+24.71%
P/S Ratio
8.97
Revenue / Employee
6.11M
Employees
5,264
Market Cap
288.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 30.35B | 5.37B | 21.49% |
| Mar 31, 2024 | 24.98B | 3.01B | 13.67% |
| Mar 31, 2023 | 21.98B | 5.47B | 33.13% |
| Mar 31, 2022 | 16.51B | 3.21B | 24.13% |
| Mar 31, 2021 | 13.30B | 2.07B | 18.46% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |